Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Colby who wrote (5234)	2/2/1998 2:46:00 PM
From: Zebra 365	Read Replies (1) \| Respond to of 23519

The "587" patent, I believe Gene was referencing claim # 6 Message 3309112 RT: Check the detail of the HVSF patent claims. If you are heavily invested have a patent Atty give you an opinion don't trust me. Reference the "587" patent referred to here many times. Gene Voss 4801587 : Impotence ointment --------------------------------------------------------------------- INVENTORS: Voss; Gene, San Antonio, TX 78232 Eichler; Allen C., San Antonio, TX 78213 ASSIGNEES: none ISSUED: Jan.ÿ31, 1989 ÿ FILED: Mar.ÿ2 , 1987 SERIAL NUMBER: 020544 ÿ MAINT. STATUS: INTL.ÿCLASS (Ed.ÿ4): A61K 031/47; A61K 031/50; U.S. CLASS: 514/248; 514/307; 514/400; 514/502; 514/649; 514/947; FIELD OF SEARCH: 514-307,400,248,502,649 ; 12 CLAIMS I claim: ÿÿÿÿ1. A method of relieving impotence comprising the single step of applying an ointment to the skin around the penis, said ointment comprising: a primary agent, being a vasodilator, selected from the group consisting of papaverine, hydralazine, sodium nitroprusside, phenoxybenzamine or phentolamine, said primary agent being present in said ointment in an amount between one and five percent by weight; dimethyl sulfoxide for assisting absorption of said primary agent through said skin; and a base. ÿÿÿÿ2. The method of claim 1 wherein said ointment is applied to the glans portion of the penis. ÿÿÿÿ3. A method of relieving impotence comprising the steps of: applying a first ointment to the skin around the penis, said first ointment containing only a carrier for assisting absorption of a primary agent through said skin; removing said first ointment from said skin after a short period of time; and applying a second ointment to said skin said second ointment containing said primary agent, wherein said primary agent is selected from the group consisting of papaverine, hydralazine, sodium nitroprusside, phenoxybenzamine and phentolamine, and said primary agent is present in said second ointment in an amount between one and five percent by weight. ÿÿÿÿ4. The method of claim 3 wherein said carrier is dimethoxy sulfoxide. ÿÿÿÿ5. The method of claim 3 wherein said first and second ointments are applied to the glans portion of said penis. ÿÿÿÿ6. A method of relieving impotence comprising the steps of: placing a catheter within the urethra of the penis, said catheter being in fluid communication with a tube, said tube containing an ointment, said ointment comprising a primary agent and a base, wherein said primary agent is a vasodilator and is present in an amount of between one and five percent by weight; and squeezing said tube thereby extruding said ointment into said catheter and into said urethra. ÿÿÿÿ7. The method of claim 6 wherein said primary agent is selected from the group consisting of papaverine, hydralazine, sodium nitroprusside, phenoxybenzamine and phentolamine. ÿÿÿÿ8. The method of claim 6 wherein said ointment further comprises a carrier for assisting absorption of said primary agent through the wall of said urethra. ÿÿÿÿ9. The method of claim 8 wherein said carrier is dimethoxy sulfoxide. ÿÿÿÿ10. A method of relieving impotence comprising the steps of: surgically removing a portion of the fibrous sheath surrounding the corpora cavernosa within the penis; and applying an ointment to the skin around said penis, said ointment comprising a primary agent, being a vasodilator, and a base, said primary agent being present in an amount of between one and five percent by weight. ÿÿÿÿ11. The method of claim 10 wherein said primary agent is selected from the group consisting of papaverine, hydralazine, sodium nitroprusside, phenoxybenzamine and phentolamine. ÿÿÿÿ12. The method of claim 10 wherein said ointment further comprises a carrier for missing absorption of said primary agent through the wall of said urethra. --------------------------------------------------------------- Zebra

To: Colby who wrote (5234)	2/2/1998 2:50:00 PM
From: jack w garnes jr.	Read Replies (2) \| Respond to of 23519

Hi Colby, I believe that TA being a MD that knows lot about this subject can answer your quesitions. She can explain it alot better than me. Its like I said before I own both HVSF and VVUS. I feel that I can make money both ways. With respect to VVUS Im holding long term. Im looking to make money in the short term on HVSF. Im looking for phase II clinical trials tobe approved in april. I also think there going to get there applicator approved. Another person that I feel can answer your quesitions is DR. Voss. Regards JG